Evidence map›Paper›PMID 38756074›Full record

Observational studyRecent patents on anti-cancer drug discovery2025

Stem Cell Markers in Neoplasms and their Relationship with Progression-free and Overall Survival in Patients with Recurrence.

Aldo Eguiluz-Melendez, Carmen Rubio-Osornio, Artemio Rosiles-Abonce, Cesar Mendoza, Miryam Ramirez-Ordas, Romina Rivera-Canas, Martha Tena-Suck, Juan Luis Gomez-Amador, Sergio Moreno-Jimenez

Abstract readObservational Study
PubMed Publisher
In one paragraph

Observational study in Recent patents on anti-cancer drug discovery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Aldo Eguiluz-MelendezNeurosurgery Department, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico.
Carmen Rubio-OsornioNeurophysiology Department, National Institute of Neurology and Neurosurgery, Mexico City, Mexico.
Artemio Rosiles-AbonceNeurophysiology Department, National Institute of Neurology and Neurosurgery, Mexico City, Mexico.
Cesar MendozaNeurophysiology Department, National Institute of Neurology and Neurosurgery, Mexico City, Mexico.
Miryam Ramirez-OrdasNeurosurgery Department, Instituto Nacional de Neurología y Neurocirugía Manuel Velasco Suárez, Mexico City, Mexico.
Romina Rivera-CanasNeuroradiology Department, Instituto Nacional de Neurología y Neurocirugía Manuel Velasco Suárez, Mexico City, Mexico.
Martha Tena-SuckNeuropathology Department, National Institute of Neurology and Neurosurgery, Mexico City, Mexico.
Juan Luis Gomez-AmadorNeurosurgery Department, Instituto Nacional de Neurología y Neurocirugía Manuel Velasco Suárez, Mexico City, Mexico.
Sergio Moreno-JimenezNeurosurgery Department, Instituto Nacional de Neurología y Neurocirugía Manuel Velasco Suárez, Mexico City, Mexico.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundGliomas account for 30% of primary brain tumors in adults, and despite the scientific progress in the field, recurrence is prevalent. Glioma Stem Cells (GSCs) can generate tumor cells

methodsIn this observational study, we have retrospectively analyzed 69 patients, of which 20 met the inclusion criteria. The clinical, radiological, and histopathological findings have been described, and survival analysis has been performed according to SOX expression for PFS and OS.

resultsWe found SOX1, SOX2, and SOX9 to show a non-statistically significant trend with increasing histopathological grade, co-expressed with Ki67, a cell proliferation factor.

conclusionThere has been found an inversely proportional correlation between the degree of immunopositivity of SOX1 and OS. A higher SOX1 immunopositivity could predict a worse clinical prognosis. There has also been found an interaction between a pluripotent genotype (GSC) and cell proliferation.

Indexed as

Biomarkers, TumorBrain NeoplasmsGliomaNeoplasm Recurrence, LocalNeoplastic Stem CellsAdultAgedFemaleHumansMaleMiddle AgedPrognosisProgression-Free SurvivalRetrospective StudiesSOX9 Transcription FactorSOXB1 Transcription FactorsBiomarkers, TumorSOX2 protein, humanSOX9 protein, humanSOX9 Transcription FactorSOXB1 Transcription FactorsGliomasglioma stem cells.Ki67SOX1SOX2SOX3SOX9

Identifiers

PMID38756074

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.